Asrani S, Robin AL, Serle JB, et al. Netarsudil/latanoprost fixed-dose combination for elevated intraocular pressure: 3-month data from a randomized phase 3 trial. Am J Ophthalmol. 2019. doi: 10.1016/j.ajo.2019.06.016. [Epub ahead of print].
Cairns JE. Trabeculectomy. Preliminary report of a new method. Am J Ophthalmol. 1968;66:673-679.
Crawley L, Zamir SM, Cordeiro MF, et al. Clinical options for the reduction of elevated intraocular pressure. Ophthalmol Eye Dis. 2012;4:43-64.
Drance SM. Glaucoma treated with diamox; preliminary report of 20 cases. Br J Ophthalmol. 1955;39:659-663.
Fox AR, Risma TB, Kam JP, Bettis DI. MIGS: Minimally invasive glaucoma surgery. EyeRounds.org. https://webeye.ophth.uiowa.edu/eyeforum/tutorials/migs/. Posted September 27, 2017. Accessed September 26, 2019.
Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393:1505-1516.
Grover DS, Flynn WJ, Bashford KP, et al. Performance and safety of a new ab interno gelatin stent in refractory glaucoma at 12 months. Am J Ophthalmol. 2017;183:25-36.
Grover DS, Smith O, Fellman RL, et al. Gonioscopy-assisted transluminal trabeculotomy: an ab interno circumferential trabeculotomy: 24 months follow-up. J Glaucoma. 2018;27:393-401.
Katz IM, Hubbard WA, Getson AJ, et al. Intraocular pressure decrease in normal volunteers following timolol ophthalmic solution. Invest Ophthalmol. 1976;15:489-492.
Khouri AS, Serle JB, Bacharach J, et al. Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study. Am J Ophthalmol. 2019;204:97-104.
Lagrange H. The surgical treatment of chronic glaucomatous ocular hypertension. Br J Ophthalmol. 1937;21:477-496.
Laios K, Moschos MM, Androutsos G. Louis de Wecker (1832-1906) and his innovations in ocular surgery. Surg Innov. 2016;23:640-641.
Malihi M, Moura Filho ER, Hodge DO, et al. Long-term trends in glaucoma-related blindness in Olmsted County, Minnesota. Ophthalmology. 2014;121:134-141.
Medeiros FA, Martin KR, Peace J, et al. Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR study. Am J Ophthalmol. 2016;168:250-259.
Molteno AC. New implant for drainage in glaucoma. Animal trial. Br J Ophthalmol. 1969;53:161-168.
Packer M, Brandt JD. Ophthalmology's botanical heritage. Surv Ophthalmol. 1992;36:357-365.
Peters D, Bengtsson B, Heijl A. Lifetime risk of blindness in open-angle glaucoma. Am J Ophthalmol. 2013;156:724-730.
Pfeiffer N, Garcia-Feijoo J, Martinez-de-la-Casa JM, et al. A randomized trial of a Schlemm's canal microstent with phacoemulsification for reducing intraocular pressure in open-angle glaucoma. Ophthalmology. 2015;122:1284-1293.
Preziosi CL. The electro-cautery in the treatment of glaucoma. Br J Ophthalmol. 1924;8:414–417.
Samuelson TW, Chang DF, Marquis R, et al. A Schlemm canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: the HORIZON study. Ophthalmology. 2019;126:29-37.
Samuelson TW, Katz LJ, Wells JM, et al. Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. Ophthalmology. 2011;118:459-467.
Samuelson TW, Sarkisian SR Jr, Lubeck DM, et al. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results. Ophthalmology. 2019;126:811-821.
Scheie HG. Retraction of scleral wound edges; as a fistulizing procedure for glaucoma. Am J Ophthalmol. 1958;45:220-229.
Serle JB, Katz LJ, McLaurin E, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: rho kinase elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116-127.
Vold S, Ahman II, Craven ER, et al. Two-year COMPASS Trial results: Supraciliary microstenting with phacoemulsification in patients with open-angle glaucoma and cataracts. Ophthalmology. 2016:123:2103-2112.
Weinreb RN, Liebmann JM, Martin KR, et al. Latanoprostene bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: pooled phase 3 study findings. J Glaucoma. 2018;27:7-15.
Weinreb RN, Ong T, Scassellati Sforzolini B, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99:738-745.
Weinreb RN, Scassellati Sforzolini B, Vittitow J, et al. Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study. Ophthalmology. 2016;123:965-973.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

Jonathan S. Myers, MD

Chief, Glaucoma Service
Wills Eye Hospital
Associate Professor
Sidney Kimmel Medical College at Thomas Jefferson University
Philadelphia, Pennsylvania

Disclosures

Disclosure: Jonathan S. Myers, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Aerie; Allergan, Inc.; Glaukos; MicroOptx
Served as a speaker or a member of a speakers bureau for: Aerie; Allergan, Inc.
Received grants for clinical research from: Aerie; Allergan, Inc.; Bausch & Lomb Inc.; Diopsys; Glaukos; Heidelberg; Novartis Pharmaceuticals Corporation; SightSciences; Zeiss

Editors

Pakinam Aboulsaoud, Pharm D

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Pakinam Aboulsaoud, PharmD, has disclosed no relevant financial relationships.

Carol Smyth, MB

Director of Content Development, Medscape, LLC

Disclosure: Carol Smyth, MB, has disclosed no relevant financial relationships.

Content Reviewers

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME

Setting the Stage for Lowering IOP in Glaucoma: Solving the Mystery of Meds, MIGS, or Combination Treatment

Authors: Jonathan S. Meyers, MD
CME Released: 11/15/2019
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 11/15/2020, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for glaucoma specialists, comprehensive ophthalmologists, and other healthcare providers interested in glaucoma management.

The goal of this activity is to enhance physicians' knowledge of pharmaceutical and surgical approaches to glaucoma treatment, as well as selecting and tailoring individualized glaucoma treatment based on patient characteristics.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Safety and efficacy of pharmaceutical and surgical (minimally invasive glaucoma surgery [MIGS], lasers, etc) approaches to glaucoma treatment
- Similarities and differences in mechanisms of surgical and nonsurgical approaches to glaucoma treatment
Have greater competence related to
- Selecting first-line treatment strategies for patients with glaucoma
- Selecting an intraocular pressure (IOP)-lowering strategy for patients who have not adequately responded to initial treatment
Demonstrate greater confidence in their ability to
- Tailor glaucoma treatment based on individual patient characteristics

Disclosures

Moderator

Jonathan S. Myers, MD

Chief, Glaucoma Service
Wills Eye Hospital
Associate Professor
Sidney Kimmel Medical College at Thomas Jefferson University
Philadelphia, Pennsylvania

Disclosures

Disclosure: Jonathan S. Myers, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Aerie; Allergan, Inc.; Glaukos; MicroOptx
Served as a speaker or a member of a speakers bureau for: Aerie; Allergan, Inc.
Received grants for clinical research from: Aerie; Allergan, Inc.; Bausch & Lomb Inc.; Diopsys; Glaukos; Heidelberg; Novartis Pharmaceuticals Corporation; SightSciences; Zeiss

Editors

Pakinam Aboulsaoud, Pharm D

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Pakinam Aboulsaoud, PharmD, has disclosed no relevant financial relationships.

Carol Smyth, MB

Director of Content Development, Medscape, LLC

Disclosure: Carol Smyth, MB, has disclosed no relevant financial relationships.

Content Reviewers

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Wills Eye Hospital designates the enduring portion of this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
[email protected]

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Ophthalmology

CME

Setting the Stage for Lowering IOP in Glaucoma: Solving the Mystery of Meds, MIGS, or Combination Treatment

Authors: Jonathan S. Meyers, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 11/15/2019

Valid for credit through: 11/15/2020, 11:59 PM EST

processing....

CME Information Download Slides

Full Live Event Audio

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Moderator

Jonathan S. Myers, MD

Editors

Pakinam Aboulsaoud, Pharm D

Carol Smyth, MB

Content Reviewers

Esther Nyarko, PharmD

Peer Reviewer

CME

Setting the Stage for Lowering IOP in Glaucoma: Solving the Mystery of Meds, MIGS, or Combination Treatment

Target Audience and Goal Statement

Disclosures

Moderator

Jonathan S. Myers, MD

Editors

Pakinam Aboulsaoud, Pharm D

Carol Smyth, MB

Content Reviewers

Esther Nyarko, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Setting the Stage for Lowering IOP in Glaucoma: Solving the Mystery of Meds, MIGS, or Combination Treatment